Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Glucose-induced sympathetic activity and energy expenditure during acute alpha(2)-adrenergic antagonism in obese subjects
Autore:
Thalamas, C; Galitzky, J; Senard, JM; Lafontan, M; Montastruc, JL; Berlan, M; Barbe, P;
Indirizzi:
CHU Toulouse, Ctr Invest Clin, Toulouse, France CHU Toulouse Toulouse France oulouse, Ctr Invest Clin, Toulouse, France INSERM U317, Toulouse, France INSERM U317 Toulouse FranceINSERM U317, Toulouse, France
Titolo Testata:
INTERNATIONAL JOURNAL OF OBESITY
fascicolo: 6, volume: 24, anno: 2000,
pagine: 695 - 700
SICI:
0307-0565(200006)24:6<695:GSAAEE>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
INDUCED THERMOGENESIS; WEIGHT-LOSS; YOHIMBINE; LIPOLYSIS; ADRENOCEPTORS; HUMANS; WOMEN;
Keywords:
sympathetic nervous system; diet induced thermogenesis; facultative thermogenesis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Thalamas, C CHU Toulouse, Ctr Invest Clin, Toulouse, France CHU Toulouse Toulouse France Invest Clin, Toulouse, France
Citazione:
C. Thalamas et al., "Glucose-induced sympathetic activity and energy expenditure during acute alpha(2)-adrenergic antagonism in obese subjects", INT J OBES, 24(6), 2000, pp. 695-700

Abstract

OBJECTIVE: To determine the effect of an alpha(2)-adrenoceptor antagonist,idazoxan, on the sympathetic nervous system and on energy expenditure responses after an oral glucose load, in obese patients. (idazoxan acts as an indirect sympathomimetic drug through blockade of presynaptic alpha(2)-adrenoceptors). DESIGN: Double-blind randomized placebo-controlled cross-over study. Idazoxan (40 mg) or placebo were administered orally 90 min before a 100 g oral glucose load. SUBJECTS: Twelve long-standing obese subjects (six men and six women, age range from 24 to 45 y. body mass index range from 30.2 to 41.3 kg/m(2)). MEASUREMENTS: Energy expenditure was derived from oxygen consumption and carbon dioxide production according to indirect calorimetry. Plasma samples were obtained for plasma adrenaline and noradrenaline, glucose, non-esterified fatty acid (NEFA), glycerol and insulin determinations. RESULTS: The plasma noradrenaline concentration response to the glucose load was significantly higher after idazoxan than after placebo administration. The time-course of glucose load-induced thermogenesis was not significantly different after administration of idazoxan nor placebo. Idazoxan administration did not modify the insulin, non-esterified fatty acids or glycerolconcentration responses to the glucose load. Neither heart rate nor blood pressure values were modified by idazoxan when compared to placebo. However, idazoxan significantly improved glucose tolerance. CONCLUSION: The alpha(2)-adrenergic antagonist idazoxan increases glucose-induced sympathetic activity but not energy expenditure in obese subjects. These data do not argue for the development of alpha(2)AR antagonist compounds as antiobesity treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 10:06:33